Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study

Aim    To study the etiology and the dynamics of prevalence and mortality of CHF; to evaluate the treatment coverage of such patients in a representative sample of the European part of the Russian Federation for a 20-year period. 
Material and methods    A representative sample of the European part of the Russian Federation followed up for 2002 through 2017 (n=19 276); a representative sample of the population of the Nizhny Novgorod region examined in 1998 (n=1922).
Results    During the observation period since 2002, the incidence of major CHF symptoms (tachycardia, edema, shortness of breath, weakness) tended to decrease while the prevalence of cardiovascular diseases has statistically significantly increased. During the period from 1998 through 2017, the prevalence of I-IV functional class (FC) CHF increased from 6.1 % to 8.2 % whereas III-IV FC CHF increased from 1.8 % to 3.1 %. The main causes for the development of CHF remained arterial hypertension and ischemic heart disease; the role of myocardial infarction and diabetes mellitus as causes for CHF was noted. For the analyzed period, the number of treatment components and the coverage of basic therapy for patients with CHF increased, which probably accounts for a slower increase in the disease prevalence by 2007–2017. The prognosis of patients was unfavorable: in I-II FC CHF, the median survival was 8.4 (95 % CI: 7.8–9.1) years and in III-IV FC CHF, the median survival was 3.8 (95 % CI: 3.4–4.2) years.

1. Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR et al. Temporal Trends in the Incidence of and Mortality Associated with Heart Failure with Preserved and Reduced Ejection Fraction. JACC: Heart Failure. 2018;6(8):678–85. DOI: 10.1016/j.jchf.2018.03.006

2. Vinogradova N.G., Polyakov D.S., Fomin I.V. Analysis of mortality in patients with heart failure after decompensation during longterm follow-up in specialized medical care and in real clinical practice. Kardiologiia. 2020;60(4):91–100. DOI: 10.18087/cardio.2020.4.n1014

3. Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF et al. Heart Failure with Preserved, Borderline, and Reduced Ejection Fraction. Journal of the American College of Cardiology. 2017;70(20):2476–86. DOI: 10.1016/j.jacc.2017.08.074

4. Gerber Y, Weston SA, Enriquez-Sarano M, Berardi C, Chamberlain AM, Manemann SM et al. Mortality Associated with Heart Failure After Myocardial Infarction: A Contemporary Community Perspective. Circulation: Heart Failure. 2016;9(1):e002460. DOI: 10.1161/CIRCHEARTFAILURE.115.002460

5. Boytsov S.A., Balanova Yu.A., Shal’nova S.A., Deev A.D., Artamonova G.V., Gatagonova T.M. et al. Arterial hypertension among persons aged 25-64: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4–14. DOI: 10.15829/1728-8800-2014-4-4-14

6. Xanthakis V, Enserro DM, Larson MG, Wollert KC, Januzzi JL, Levy D et al. Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. JACC: Heart Failure. 2016;4(10):808–15. DOI: 10.1016/j.jchf.2016.05.001

7. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP et al. Heart Disease and Stroke Statistics–2019 Update: A Report from the American Heart Association. Circulation. 2019;139(10):e56–528. DOI: 10.1161/CIR.0000000000000659

8. The Consensus Trial Study Group*. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. New England Journal of Medicine. 1987;316(23):1429–35. DOI: 10.1056/NEJM198706043162301

9. DeVore AD, Thomas L, Albert NM, Butler J, Hernandez AF, Patterson JH et al. Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. American Heart Journal. 2017; 189:177–83. DOI: 10.1016/j.ahj.2017.04.010

10. Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Pannaux M et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. European Journal of Heart Failure. 2018;20(9):1315–22. DOI: 10.1002/ejhf.1234

11. Gelbrich G, Störk S, Kreißl-Kemmer S, Faller H, Prettin C, Heuschmann PU et al. Effects of structured heart failure disease management on mortality and morbidity depend on patients’ mood: results from the Interdisciplinary Network for Heart Failure Study: Effects of structured HF management depend on patients’ mood. European Journal of Heart Failure. 2014;16(10):1133–41. DOI: 10.1002/ejhf.150

12. Van Spall HGC, Rahman T, Mytton O, Ramasundarahettige C, Ibrahim Q, Kabali C et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis: Comparative effectiveness of transitional care services in patients hospitalized with heart failure. European Journal of Heart Failure. 2017;19(11):1427–43. DOI: 10.1002/ejhf.765

13. Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. European Journal of Preventive Cardiology. 2021;zwaa147. [Epub ahead of print]. DOI: 10.1093/eurjpc/zwaa147

14. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. European Journal of Heart Failure. 2020;22(8):1342–56. DOI: 10.1002/ejhf.1858

15. Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016; 8:7–13. DOI: 10.15829/1560-4071-2016-8-7-13

16. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61. DOI: 10.1161/CIR.0000000000000509

17. Taylor CJ, Ordóñez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ. 2019; 364:l223. DOI: 10.1136/bmj.l223

18. Di Tano G, De Maria R, Gonzini L, Aspromonte N, Di Lenarda A, Feola M et al. The 30-day metric in acute heart failure revisited: data from IN-HF Outcome, an Italian nationwide cardiology registry. European Journal of Heart Failure. 2015;17(10):1032–41. DOI:10.1002/ejhf.290

19. Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Badin Yu.V., Galyavich A.S. et al. Prevalence of CHF in European part of the Russian Federation: data from EPOCH-CHF. Russian Heart Failure Journal. 2006;7(1):4–7.

20. Shechrbinina E.V., Badin Yu.V., Vaysberg A.R. Dynamics of the etiological causes of CHF formation in a representative sample of the Nizhny Novgorod region over 9 years of follow-up (1998-2007). AllRussian Conference of CHF: “Heart failure, 2007”. – M., 2007. – P. 38.

21. Mareev V.Yu., Belenkov Yu.N., Ageev F.T., Fomin I.V., Chochlov R.A., Galiavich A.S. et al. The first results of Russian epidemiological studies with CHF (EPOCHA-CHF). Russian Heart Failure Journal. 2003;4(1):17–8.

22. Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Fomin I.V., Badin Yu.V., Polyakov D.S. et al. Veritable prevalence of CHF in the European part of Russian Federation (EPOCHA trial, hospital stage). Russian Heart Failure Journal. 2011;12(2):63–8.

23. The World Bank. Population, total. Demographic Statistics. [Internet] Available at: https://data.worldbank.org/indicator/SP.POP.TOTL

24. Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology: Advanced heart failure: HFA position statement. European Journal of Heart Failure. 2018;20(11):1505–35. DOI: 10.1002/ejhf.1236

25. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128

26. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407–77. DOI: 10.1093/eurheartj/ehz425

27. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-327. DOI: 10.1161/CIR.0b013e31829e8776

28. Ho JE, Zern EK, Wooster L, Bailey CS, Cunningham T, Eisman AS et al. Differential Clinical Profiles, Exercise Responses, and Outcomes Associated With Existing HFpEF Definitions. Circulation. 2019;140(5):353–65. DOI: 10.1161/CIRCULATIONAHA.118.039136

29. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–158. DOI: 10.18087/cardio.2475

30. Mareev Yu.V., Garganeeva A.A., Tukish O.V., Rebrova T.Yu., Anikina D.V., Mareev V.Yu. Difficulties in diagnosis of heart failure with preserved ejection fraction in clinical practice: dissonance between echocardiography, NTproBNP and H2HFPEF score. Kardiologiia. 2020;59(12S):37–45. DOI: 10.18087/cardio.n695

31. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297–317. DOI: 10.1093/eurheartj/ehz641

32. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861–70. DOI: 10.1161/CIRCULATIONAHA.118.034646

33. Selvaraj S, Myhre PL, Vaduganathan M, Claggett BL, Matsushita K, Kitzman DW et al. Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. JACC: Heart Failure. 2020;8(8):640–53. DOI: 10.1016/j.jchf.2020.03.013

34. Gudieva Kh.M., Safarova A.F., Kobalava Zh.D. Use of the HFA-PEFF algorithm for diagnosis of heartfailure with preserved left ventricular ejection fraction. Clinical pharmacology and therapy. 2020;29(2):47–50. DOI: 10.32756/0869-5490-2020-2-47-50

35. Bjork JB, Alton KK, Georgiopoulou VV, Butler J, Kalogeropoulos AP. Defining Advanced Heart Failure: A Systematic Review of Criteria Used in Clinical Trials. Journal of Cardiac Failure. 2016;22(7):569–77. DOI: 10.1016/j.cardfail.2016.03.003

36. Fang JC, Ewald GA, Allen LA, Butler J, Westlake Canary CA, ColvinAdams M et al. Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure. 2015;21(6):519–34. DOI: 10.1016/j.cardfail.2015.04.013

37. Huffman MD, Berry JD, Ning H, Dyer AR, Garside DB, Cai X et al. Lifetime Risk for Heart Failure Among White and Black Americans: cardiovascular lifetime risk pooling project. Journal of the American College of Cardiology. 2013;61(14):1510–7. DOI: 10.1016/j.jacc.2013.01.022

38. Barker WH. Changing Incidence and Survival for Heart Failure in a Well-Defined Older Population, 1970-1974 and 1990-1994. Circulation. 2006;113(6):799–805. DOI: 10.1161/CIRCULATIONAHA.104.492033

39. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Internal Medicine. 2015;175(6):996–1004. DOI: 10.1001/jamainternmed.2015.0924

40. Bibbins-Domingo K, Pletcher MJ, Lin F, Vittinghoff E, Gardin JM, Arynchyn A et al. Racial Differences in Incident Heart Failure among Young Adults. New England Journal of Medicine. 2009;360(12):1179–90. DOI: 10.1056/NEJMoa0807265

41. Chen J, Normand S-LT, Wang Y, Krumholz HM. National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008. JAMA. 2011;306(15):1669–78. DOI: 10.1001/jama.2011.1474

42. Alehagen U, Benson L, Edner M, Dahlström U, Lund LH. Association between use of statins and mortality in patients with heart failure and ejection fraction of ≥50. Circulation. Heart Failure. 2015;8(5):862–70. DOI: 10.1161/CIRCHEARTFAILURE.115.002143

43. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J et al. Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. Journal of the American College of Cardiology. 2017;69(24):2885–96. DOI: 10.1016/j.jacc.2017.04.001

44. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR et al. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF). European Journal of Heart Failure. 2014;16(7):817–25. DOI: 10.1002/ejhf.115

45. Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O’Connor CM. Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. JACC: Heart Failure. 2016;4(2):109–15. DOI: 10.1016/j.jchf.2015.09.002

46. Ferrari R. A step further with ivabradine: SIGNIfY (Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease). European Heart Journal Supplements. 2009;11(Suppl D):D19–27. DOI: 10.1093/eurheartj/sup014

47. Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. The Lancet. 2019;393(10175):1034–44. DOI: 10.1016/S0140-6736(18)31808-7

48. Van Spall HGC, Lee SF, Xie F, Oz UE, Perez R, Mitoff PR et al. Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial. JAMA. 2019;321(8):753–61. DOI: 10.1001/jama.2019.0710

49. Laborde-Castérot H, Agrinier N, Zannad F, Mebazaa A, Rossignol P, Girerd N et al. Effectiveness of a multidisciplinary heart failure disease management programme on 1-year mortality: Prospective cohort study. Medicine. 2016;95(37):e4399. DOI: 10.1097/MD.0000000000004399

50. Vinogradova N.G. City Center for the Treatment of Chronic Heart Failure: the organiza-tion of work and the effectiveness of treatment of patients with chronic heart failure. Kardiologiia. 2019;59(2S):31–9. DOI: 10.18087/cardio.2621